Temperature sensitive mutants of Mycoplasma pneumoniae were developed with the expectation that their temperature sensitive defects would restrict replication in vivo at the temperature of the lower respiratory tract, whereas such defects would not seriously impair replication in the cooler environment of the upper respiratory passages. One such ts mutants ts-H43, which does not replicate at a temperature of 370 qr above, although noninfectious for hamsters, infected each of 16 seronegative adult volunteers when given by the intranasal route. The mutant remained genetically stable throughout the course of infection and stimulated a moderate systemic and local antibody response. The mutant was entirely avirulent for the volunteers but appeared to stimulate resistance to subsequent challenge with partially attenuated wild-type (ts+) Mycoplasmapneumoniae.
Mycoplasma pneumoniae, the etiologic agent of primary atypical pneumonia associated with cold agglutinins, is an important cause of respiratory disease in older children and young adults (1, 2) . In some closed populations of military recruits, the organism can assume major importance since it causes pneumonia with a frequency 20 times that seen in the general civilian population (3) . Although Al. pneumoniae pneumonia responds satisfactorily to treatment with the appropriate antibiotic, the organism is not eradicated from the respiratory tract (4) . Furthermore, the onset of disease is often insidious and considerable debility can occur before the illness is diagnosed correctly. For these reasons, an effective vaccine would be desirable for prevention of M. pneumoniae disease.
Critical to the development of effective immunoprophylaxis is an understanding of the pathogenesis of the disease and the host defense mechanisms which prevent the illness. Although there are many gaps in our knowledge in this area, several relevant findings have emerged from recent studies. Infection with the organism under experimental conditions appears to be quite superficial, involving only the respiratory epithelium (5) . This suggests that local immune mechanisms in the respiratory tract should be of greater importance than systemic immunity in protecting against disease. This inference can also be drawn from the finding that resistance to experimental challenge in the hamster was stimulated more effectively by infection or intranasal instillation of inactivated organisms than by parenteral inoculation of inactivated M. pneumoniae, although the latter method stimulated higher levels of serum Abbreviations: MI, metabolism-inhibiting, CF, complement fixation; MCT, complement dependent mycoplasmacidal; RIP radioimmunoprecipitation; CFU, colony forming unit; NTG, Nmethyl-N'-nitro-N-nitrosoguanidine; ts, temperature sensitive. 4015 antibody (ref. 6 and unpublished data). In a recent study, we detected the development of local respiratory IgA antibody for M. pneumoniae in man after experimental infection with the organism. Preexisting local antibody appeared to be more closely correlated with resistance to disease than was serum antibody (7) . These findings further support the view that local immune mechanisms (secretory immunoglobulin and/or cell mediated immunity) in the respiratory tract may be of prime importance in protection from disease. These observations also provide a basis for pursuing the development of a live attenuated mutant which could be administered locally into the respiratory tract and which would stimulate local immune processes in this area.
In previous work we have described the production and characterization of a series of temperature sensitive (ts) mutants of All. pneumoniae (8, 9) . Mutants were selected which were restricted in growth on agar at 360, 370, or 380. At these temperatures, the wild-type organism grew without restriction. Missense mutants of the ts class were sought with the expectation that their temperature sensitve defects would restrict growth in vivo at the temperature Qf the lower respiratory tract (370), whereas replication would not be seriously impaired in the cooler environment of the upper respiratory passage (32°-34°). Five ts mutants of Ml. pneumoniae with restrictive temperatures between 360 and 380 were selected for in vivo studies because of their high degree of in vitro genetic stability. It was shown that these mutants were attenuated for the Syrian hamster, and prior infection with those mutants able to replicate in the hamster induced prolonged resistance to subsequent challenge with wild type organism (9) . Importantly, the mutants were completely stable genetically in vivo as well as in vitro.
The mutant with intermediate temperature sensitivity (ts-640) was the first to be evaluated in man (9) . In the laboratory ts-640 was found to be partially restricted in growth on agar at 370 and completely restricted at 380. The mutant was studied in 11 volunteers who lacked preexisting serum metabolism-inhibiting (MI) antibody. Each volunteer was infected and nine underwent a silent infection. However, two of the volunteers developed bronchitis which indicated that the mutant retained sufficient residual virulence to disqualify it as a candidate vaccine strain. Nonetheless, the results of the study were encouraging since ts-640 induced a significant antibody response in the volunteers and the mutant was genetically stable in man.
The next mutant after ts-640 in the temperature sensitivity gradient was ts-H43. This organism was completely restricted in growth on agar at 370 and was highly attenuated, being noninfectious for hamsters and guinea pigs. In contrast, ts mutants less defective than ts-H43, i.e., mutants with a higher temperature shutoff, produced an extensive, prolonged infection in these rodents. Although mutant ts-H43 lacked infectivity for hamsters and guinea pigs, we were prompted to evaluate this organism in man because a mutant which was slightly less temperature sensitive (ts-640) was infectious for man and retained some virulence. In this report we will describe the response of adult volunteers to the ts-H43 mutant.
MATERIALS AND METHODS
Organisms. The PI 1428 strain of M. pneumoniae was exposed to 100 ,ug/ml of N-methyl-N'-nitro-N-nitrosoguanidine (NTG) and mutants were selected from clonal populations produced on agar by a suspension of treated organisms which were filtered through a 220-nm Millipore filter (9) .
The ts-H43 mutant was subjected to three colony-to-colony passages and then studied for the effect of temperature on growth on agar and for its ability to infect hamsters and guinea pigs. The suspension of ts-H43 administered to volunteers was prepared after the 14th passage of the PI 1428 strain in artificial medium. The mutant was grown in a broth medium consisting of seven parts PPLO broth (Difco), two parts swine serum, and one part 25% yeast extract without thallium or penicillin. The 14th passage suspension was tested for evidence of adventitious microbial agents and none were found. In addition, the ts-H43 mutant was shown to be completely inhibited by 5 Og/ml of erythromycin or tetracycline.
The wild-type suspension of strain PI 1428 was prepared after the 3rd passage in artificial medium. It was grown in broth medium identical to that used for preparation of the ts-H43 mutant suspension described above. In studies of human volunteers, this wild-type suspension proved to be only marginally virulent and was, therefore, classified as partially attenuated.
Recovery of Organisms and Test for Genetic Stability of Isolates. Volunteers infected with either wild type or temperature sensitive organisms were tested for the presence of M. pneumoniae in their throat and sputum at 2-to 5-day intervals over a 28-to 60-day period. Throat swab fluid and sputum were inoculated in duplicate at the bedside into diphasic mycoplasma medium which was incubated at 320 and observed for color change and spherule formation over a 2-month period (10) . Fluid from presumptively positive cultures was inoculated onto agar medium and the agar plates were incubated at 320 or 380 in an air incubator. M. pneumoniae isolates were identified by (1) their ability to grow as spherules in diphasic media, (2) their colonial morphology on agar, and (3) the ability of colonies on agar to hemadsorb guinea pig erythrocytes. Temperature sensitivity of the isolates was evaluated in a preliminary fashion by comparing the efficiency of colony formation at 320 (a permissive temperature) and at 380 (a restrictive temperature). Definitive characterization of the ts phenotype was performed subsequently in tests in which incubation was carried out in water baths which were maintained at 370 or 380 4 0.050. The last isolate, from each volunteer following infection with ts-H43, was titrated and the inoculated agar cultures were incubated at 320 in an air incubator and at 370 or 380 in a water bath. Failure of the isolate to produce colonies on agar medium at the restrictive temperatures of 370 and 380 indicated that it possessed the ts phenotype of the ts-H43 mutant.
Immunologic Procedures. Serum antibody was measured by complement fixation (CF), metabolism inhibition (MI), and complement dependent mycoplasmacidal (MCT) tests as described previously (10, 11) . The radioimmunoprecipitation (RIP) test for secretory antibody was performed as described previously with two modifications (12): [3H]oleic and [3H]-palmitic acids instead of "4C-labeled fatty acids were used to label the mycoplasma. The anti-IgA serum used to precipitate M. pneumoniae-antibody complexes was produced in rabbits by Behringwerke Ag., Germany. Titer of IgA antibody was adjusted to a level of 20 mg/100 ml of IgA.
Collection and Processing of Respiratory Secretions. Nasal wash fluids and sputum samples were sonicated at 10 kHz for 2 min and centrifuged at 2000 rpm for 10 min. The supernatant obtained from the nasal washes was concentrated 10-fold by exposure to Aquacide (Calbiochem, San Diego, Calif.) whereas the supernatant from sputum was tested for antibody without further concentration. IgA content in the secretions was determined by use of the radial immunodiffusion method of Mancini et al. (13 
RESULTS
Properties of the ts-H43 Mutant. As described previously, of the five genetically stable ts mutants of M. pneumoniae investigated extensively in vitro and in vivo, the ts-H43 mutant exhibited the next to the most temperature sensitivity (9) . Three men in the 1st group, one in the 2nd group, and two in the 3rd group possessed serum MI antibody at the time of challenge, whereas men in the 4th group (controls) were seronegative.
* Sputum not available from one volunteer.
t Sputum not available from two volunteers.
N.I., no increase; IN, intranasally; iM, intramuscularly.
tions was seen less often than in sputum. Eight of the volunteers developed a 3-fold or greater increase in M. pneumoniae IgA antibody in nasal secretions. The secretory antibody responses to ts-H43 appeared to occur as frequently and to be of the same magnitude as the responses of volunteers who were infected with a partially attenuated wild-type suspension of M. pneumoniae (Tables 2  and 3 ). In addition, the secretory antibody responses of the ts-H43 infected volunteers were similar in frequency and magnitude to those described for a larger group of men infected with wild-type M. pneumoniae (7) .
Clinical Response to Infection. None of the men infected with the ts-H43 mutant developed any signs or symptoms of illness during the 28-day period of intensive medical surveillance following administration of the inoculum. There were no elevations of temperature nor did any of the men develop any signs or symptoms involving the respiratory tract. Hematocrit, white cell count and cold agglutinins were investigated weekly and there were no abnormalities noted. Similarly, SGPT (serum glutamic pyruvic transaminase) and serum alkaline phosphatase were not elevated on day 14 or day 28. Finally, chest x-rays were normal in each instance on day 28.
Response of Men Infected with ts-H43 to Later Challenge with Partially Attenuated Wild-Type M. pneumoniae. A third passage suspension of the PI 1428 strain of M. pneumoniae, which was wild type (ts+) and partially attenuated, was used as a challenge inoculum in 4n attempt to evaluate the extent of resistance induced by the ts-H43 mutant. In order to aid in this evaluation, a group of six men who did not have serum MI antibody was also challenged, as were seven men who were initially seronegative and who received an inactivated M. pneumoniae vaccine either intranasally or intramuscularly ( Table 3 ). The 3rd passage suspension of the PI 1428 strain produced illness in only two of the volunteers. Both of these men had received inactivated vaccine by the nasal route previously; they developed bronchitis with low grade fever and these symptoms responded rapidly to treatment with erythromycin.
It was not possible to assess the capacity of ts-H43 to induce resistance to disease since the challenge inoculum did not produce objective signs of illness with sufficient frequency to permit such an analysis. However, there was a suggestion that infection with the ts+ suspension of M. pneumoniae was suppressed in men who had received the ts-H43 mutant previously (Table 3 ). The ts-H43 vaccinees failed to develop a serum antibody response, whereas 12 of the 13 men in the comparison groups developed a seroresponse. Further, ts-H48 vaccinees appeared to shed fewer organisms from the respiratory tract than the seronegative controls or the men who had received inactivated M. pneumoniae vaccine previously. ts-H43 vaccinees also appeared to have local respiratory secretory antibody responses which were less extensive than those observed in men in the seronegative control and inactivated vaccine groups.
DISCUSSION
An organism, to be used in a live vaccine, must achieve a very delicate balance between attenuation and the ability to replicate sufficiently well so that the defense mechanisms of the host are stimulated. In a previous study of (7, 11) . While this antibody is specific in that it is capable of lysing the organ sm in the presence of complement and can be blocked by M. pneumoniae organisms, its origin remains unclear. Whether this pre-existing antibody represents prior silent infection with M. pneumoniae or whether it is induced by exposure to common naturally occurring cross-reactive glycolipid antigens remains to be established.
Preliminary observations from a challenge of ts-H43 vaccinees with partially attenuated wild type (ts+) M. pneumoniae suggested that the mutant had induced resistance to infection. In the challenge study, resistance to illness could not be evaluated; however, infection with wild type (ts+) organisms appeared to be suppressed in men previously given the ts-H43 mutant. Previous studies in animals have shown that resistance to infection is conferred on a host only by prior infection of the respiratory tract with M. pneumoniae (ref. 6 and unpublished data). It appears that inactivated vaccines given either systemically or locally do not induce resistance to infection of the respiratory tract although the host may be protected against the development of lung lesions.
Another property desirable in a live vaccine is genetic stability. Initially, the ts-H43 mutant was chosen for further study in vitro and in animals because of its failure to produce wild-type revertants during growth to high titer in broth medium (9) . In the present study, the mutant also appeared to be stable genetically in man in that none of the isolates recovered from infected volunteers exhibited evidence of reversion of the ts phenotype. ts-H43 was induced by exposure of wild-type M. pneumoniae to 100 ,ug/ml of NTG (9) . In this circumstance it is likely that the mutant sustained more than one tA point mutation. Further, the presence of more than one ts lesion probably accounts for the genetic stability of ts-H43. Adelberg , Mandel, and Chen have commented upon the tendency for NTG to produce multiple genetic lesions, some of which are not temperature sensitive, in bacteria (15) . As in bacteria mutagenized by NTG, non-ts genetic lesions may also be present in t8-H43.
In practical terms, the results of the first volunteer studies with ts-H43 are sufficiently encouraging to warrant cautious expansion of evaluation of the mutant in larger numbers of volunteers. Furthermore, while several attempts to use temperature sensitive mutants of respiratory viruses for vaccine purposes have yielded encouraging results (16, 17) , the present effort represents the first application of this technique to freeliving organisms. The promising results presented here may offer a new approach toward the control of other bacterial respiratory pathogens.
